A detailed history of Stonepine Capital Management, LLC transactions in Galapagos Nv stock. As of the latest transaction made, Stonepine Capital Management, LLC holds 478,659 shares of GLPG stock, worth $13 Million. This represents 8.71% of its overall portfolio holdings.

Number of Shares
478,659
Previous 485,000 1.31%
Holding current value
$13 Million
Previous $12 Billion 14.66%
% of portfolio
8.71%
Previous 10.97%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$24.2 - $30.67 $153,452 - $194,478
-6,341 Reduced 1.31%
478,659 $13.8 Billion
Q2 2024

Aug 13, 2024

BUY
$24.78 - $32.48 $2.26 Million - $2.97 Million
91,366 Added 23.21%
485,000 $12 Billion
Q1 2024

May 14, 2024

BUY
$32.2 - $42.44 $4.24 Million - $5.59 Million
131,764 Added 50.32%
393,634 $12.7 Billion
Q4 2023

Feb 13, 2024

SELL
$31.87 - $40.71 $17.2 Million - $22 Million
-540,674 Reduced 67.37%
261,870 $10.6 Billion
Q3 2023

Nov 13, 2023

BUY
$34.17 - $42.98 $27.4 Million - $34.5 Million
802,544 New
802,544 $27.7 Billion
Q2 2023

Aug 11, 2023

SELL
$37.4 - $44.52 $3.73 Million - $4.44 Million
-99,625 Reduced 12.74%
682,664 $27.8 Million
Q1 2023

May 12, 2023

BUY
$36.5 - $48.0 $21.4 Million - $28.2 Million
587,453 Added 301.51%
782,289 $30.2 Million
Q4 2022

Feb 14, 2023

BUY
$37.44 - $46.51 $7.29 Million - $9.06 Million
194,836 New
194,836 $8.65 Million
Q4 2021

Feb 14, 2022

SELL
$47.03 - $57.12 $11.5 Million - $13.9 Million
-244,205 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$52.17 - $70.2 $12.2 Million - $16.4 Million
234,205 Added 2342.05%
244,205 $12.8 Million
Q1 2021

May 14, 2021

BUY
$76.15 - $111.94 $761,500 - $1.12 Million
10,000 New
10,000 $771,000

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.79B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Stonepine Capital Management, LLC Portfolio

Follow Stonepine Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonepine Capital Management, LLC with notifications on news.